ExploreWatchlistsPricing
  1. JP-listed companies
  2. Astellas Pharma Inc.
  3. Financials
  4. EBITDA

Astellas Pharma Inc. (4503)

Market cap
¥4.62T
P/E ratio
18.3x
Astellas Pharma develops, manufactures, and sells pharmaceutical products globally through a network of 77 subsidiaries across the US, Europe, and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Mar 31, 2025240,171+30.98%
Mar 31, 2024183,358-23.21%
Mar 31, 2023238,767+1.44%
Mar 31, 2022235,370+12.78%
Mar 31, 2021208,703-32.76%
Mar 31, 2020310,387+0.98%
Mar 31, 2019307,370+498.31%
Mar 31, 201851,373

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat